Ayma Therapeutics Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jun 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for Apparatus and Kit For Encapsulating At Least One Compound For Therapeutic and/or Diagnostic Use in Erythrocytes (US 9,089,640) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,734,787 | Drug Delivery System In force · High confidence | In force | High confidence | |
| US 9,089,640 | Apparatus and Kit For Encapsulating At Least One Compound For Therapeutic and/or Diagnostic Use in Erythrocytes In force · High confidence | In force | High confidence | |
| US 10,286,008 | Method for Stabilising Suspensions of Red Blood Cells Encapsulating an Active Ingredient, the Suspensions Obtained In force · High confidence | In force | High confidence | |
| US 10,849,858 | Process for the Preparation of Erythrocytes Loaded with One or More Substances of Pharmaceutical Interest and So Obtained Erythrocytes In force · High confidence | In force | High confidence | |
| US 12,311,059 | Process for the Preparation of Erythrocytes Loaded with One or More Substances of Pharmaceutical Interest and So Obtained Erythrocytes In force · Medium confidence | In force | Medium confidence | |
| US 11,273,210 | Arginine Deiminase Encapsulated Inside Erythrocytes and Their Use in Treating Cancer and ARGINASE-1 Deficiency In force (reinstated) · High confidence | In force (reinstated) | High confidence |
Also on record, not counted in the 6: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.